Systematic Lymph Node Sampling and Analysis in Patients With Pancreatic Cancer

Systematic Lymph Node Sampling and Analysis in Patients Undergoing Radical Resection for Pancreatic Cancer. A National Danish Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02646462

Enrollment

200

Registered

2016-01-05

Start date

2015-06-30

Completion date

2016-12-31

Last updated

2016-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Keywords

pancreas adenocarcinoma, lymph node metastases

Brief summary

Prospective investigation of the ratio between malignant and total number of lymph nodes in predefined lymph node stations in patients resected for pancreatic adenocarcinoma. A national Danish project.

Detailed description

Lymph nodes will be sampled from the following stations in patients with adenocarcinomas of the pancreas Group 6: Infrapyloric lymph nodes (IP) Group 8: Lymph nodes around the common hepatic artery (CHA) Group 12: Lymph nodes of the hepatoduodenal ligament (HDL) Group 13: Posterior pancreaticoduodenal lymph nodes Group 14: Lymph nodes around the superior mesenteric artery (SMA) Group 17: Anterior pancreaticoduodenal lymph nodes

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

Bioptic verified pancreatic adenocarcinoma or periampullary adenocarcinoma (within 20mm of the papilla)

Exclusion criteria

Patients with non-adenocarcinoma tumors of the pancreas or periampullary region

Design outcomes

Primary

Measure	Time frame	Description
Ratio of malignant/total number of lymph nodes	12 months	Ratio between malignant and total number of lymph nodes in predefined lymph node stations

Secondary

Measure	Time frame	Description
Number of N1 patients	12 months	Number of patients with malignant lymph nodes in predefined lymph node stations

Countries

Denmark

Contacts

Primary ContactMichael B Mortensen, MD, PhD,

michael.bau.mortensen@rsyd.dk45 6541 1857

Outcome results